Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels.

Kauwe JS, Cruchaga C, Bertelsen S, Mayo K, Latu W, Nowotny P, Hinrichs AL, Fagan AM, Holtzman DM; Alzheimer's Disease Neuroimaging Initiative., Goate AM.

J Alzheimers Dis. 2010;21(3):833-42. doi: 10.3233/JAD-2010-091711.

2.

Impact of SORL1 single nucleotide polymorphisms on Alzheimer's disease cerebrospinal fluid markers.

Alexopoulos P, Guo LH, Kratzer M, Westerteicher C, Kurz A, Perneczky R.

Dement Geriatr Cogn Disord. 2011;32(3):164-70. doi: 10.1159/000332017.

3.

CALHM1 P86L polymorphism modulates CSF Aβ levels in cognitively healthy individuals at risk for Alzheimer's disease.

Koppel J, Campagne F, Vingtdeux V, Dreses-Werringloer U, Ewers M, Rujescu D, Hampel H, Gordon ML, Christen E, Chapuis J, Greenwald BS, Davies P, Marambaud P.

Mol Med. 2011 Sep-Oct;17(9-10):974-9. doi: 10.2119/molmed.2011.00154.

4.

Influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease.

Louwersheimer E, Ramirez A, Cruchaga C, Becker T, Kornhuber J, Peters O, Heilmann S, Wiltfang J, Jessen F, Visser PJ, Scheltens P, Pijnenburg YA, Teunissen CE, Barkhof F, van Swieten JC, Holstege H, Van der Flier WM; Alzheimer's Disease Neuroimaging Initiative and Dementia Competence Network..

Neurobiol Aging. 2015 Mar;36(3):1605.e13-20. doi: 10.1016/j.neurobiolaging.2014.12.007.

PMID:
25659857
5.

SORL1 genetic variants and cerebrospinal fluid biomarkers of Alzheimer’s disease.

Guo LH, Westerteicher C, Wang XH, Kratzer M, Tsolakidou A, Jiang M, Grimmer T, Laws SM, Alexopoulos P, Bujo H, Kurz A, Perneczky R.

Eur Arch Psychiatry Clin Neurosci. 2012 Sep;262(6):529-34.

PMID:
22286501
6.

Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's disease.

Kauwe JS, Cruchaga C, Karch CM, Sadler B, Lee M, Mayo K, Latu W, Su'a M, Fagan AM, Holtzman DM, Morris JC; Alzheimer's Disease Neuroimaging Initiative., Goate AM.

PLoS One. 2011 Feb 9;6(2):e15918. doi: 10.1371/journal.pone.0015918.

7.

CALHM1 P86L polymorphism does not alter amyloid-beta or tau in cerebrospinal fluid.

Giedraitis V, Glaser A, Sarajärvi T, Brundin R, Gunnarsson MD, Schjeide BM, Tanzi RE, Helisalmi S, Pirttilä T, Kilander L, Lannfelt L, Soininen H, Bertram L, Ingelsson M, Hiltunen M.

Neurosci Lett. 2010 Jan 22;469(2):265-7. doi: 10.1016/j.neulet.2009.12.011.

8.

Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.

Han MR, Schellenberg GD, Wang LS; Alzheimer's Disease Neuroimaging Initiative..

BMC Neurol. 2010 Oct 8;10:90. doi: 10.1186/1471-2377-10-90.

9.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative..

JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.

PMID:
25162367
10.

Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort.

Elias-Sonnenschein LS, Helisalmi S, Natunen T, Hall A, Paajanen T, Herukka SK, Laitinen M, Remes AM, Koivisto AM, Mattila KM, Lehtimäki T, Verhey FR, Visser PJ, Soininen H, Hiltunen M.

PLoS One. 2013;8(4):e59676. doi: 10.1371/journal.pone.0059676.

11.

SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease.

Cruchaga C, Kauwe JS, Mayo K, Spiegel N, Bertelsen S, Nowotny P, Shah AR, Abraham R, Hollingworth P, Harold D, Owen MM, Williams J, Lovestone S, Peskind ER, Li G, Leverenz JB, Galasko D; Alzheimer's Disease Neuroimaging Initiative., Morris JC, Fagan AM, Holtzman DM, Goate AM.

PLoS Genet. 2010 Sep 16;6(9):e1001101. doi: 10.1371/journal.pgen.1001101.

12.

Influence of SORL1 gene variants: association with CSF amyloid-beta products in probable Alzheimer's disease.

Kölsch H, Jessen F, Wiltfang J, Lewczuk P, Dichgans M, Kornhuber J, Frölich L, Heuser I, Peters O, Schulz JB, Schwab SG, Maier W.

Neurosci Lett. 2008 Jul 25;440(1):68-71. doi: 10.1016/j.neulet.2008.05.049.

PMID:
18541377
13.

Genetic variants of GSK3B are associated with biomarkers for Alzheimer's disease and cognitive function.

Kettunen P, Larsson S, Holmgren S, Olsson S, Minthon L, Zetterberg H, Blennow K, Nilsson S, Sjölander A.

J Alzheimers Dis. 2015;44(4):1313-22. doi: 10.3233/JAD-142025.

PMID:
25420549
14.

The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels.

Schjeide BM, Schnack C, Lambert JC, Lill CM, Kirchheiner J, Tumani H, Otto M, Tanzi RE, Lehrach H, Amouyel P, von Arnim CA, Bertram L.

Arch Gen Psychiatry. 2011 Feb;68(2):207-13. doi: 10.1001/archgenpsychiatry.2010.196.

PMID:
21300948
15.

Interrelations between CSF soluble AβPPβ, amyloid-β 1-42, SORL1, and tau levels in Alzheimer's disease.

Alexopoulos P, Guo LH, Tsolakidou A, Kratzer M, Grimmer T, Westerteicher C, Jiang M, Bujo H, Diehl-Schmid J, Kurz A, Perneczky R.

J Alzheimers Dis. 2012;28(3):543-52. doi: 10.3233/JAD-2011-110983.

PMID:
22045485
16.

Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta.

Kauwe JS, Wang J, Mayo K, Morris JC, Fagan AM, Holtzman DM, Goate AM.

Neurogenetics. 2009 Feb;10(1):13-7. doi: 10.1007/s10048-008-0150-4.

17.

Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.

Sauvée M, DidierLaurent G, Latarche C, Escanyé MC, Olivier JL, Malaplate-Armand C.

J Alzheimers Dis. 2014;41(2):377-86. doi: 10.3233/JAD-131838.

PMID:
24614902
18.

Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort.

Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T, Shaw LM, Trojanowski JQ, Potkin SG, Huentelman MJ, Craig DW, DeChairo BM, Aisen PS, Petersen RC, Weiner MW, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative..

Neurology. 2011 Jan 4;76(1):69-79. doi: 10.1212/WNL.0b013e318204a397.

19.

Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition.

Kauwe JS, Cruchaga C, Mayo K, Fenoglio C, Bertelsen S, Nowotny P, Galimberti D, Scarpini E, Morris JC, Fagan AM, Holtzman DM, Goate AM.

Proc Natl Acad Sci U S A. 2008 Jun 10;105(23):8050-4. doi: 10.1073/pnas.0801227105.

20.

GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease.

Cruchaga C, Kauwe JS, Harari O, Jin SC, Cai Y, Karch CM, Benitez BA, Jeng AT, Skorupa T, Carrell D, Bertelsen S, Bailey M, McKean D, Shulman JM, De Jager PL, Chibnik L, Bennett DA, Arnold SE, Harold D, Sims R, Gerrish A, Williams J, Van Deerlin VM, Lee VM, Shaw LM, Trojanowski JQ, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD, Peskind ER, Galasko D, Fagan AM, Holtzman DM, Morris JC; GERAD Consortium.; Alzheimer’s Disease Neuroimaging Initiative (ADNI).; Alzheimer Disease Genetic Consortium (ADGC)., Goate AM.

Neuron. 2013 Apr 24;78(2):256-68. doi: 10.1016/j.neuron.2013.02.026.

Items per page

Supplemental Content

Support Center